Mobile app for tracking symptoms in neuroendocrine tumor patients
Mobile Application to Collect PRO Data in NET Patients
This study is testing a mobile app that helps people with neuroendocrine tumors track their symptoms and quality of life to see if it improves communication with their doctors.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | King's College Hospital NHS Trust Academic / other |
| Locations | 1 site (London) |
| Trial ID | NCT04324502 on ClinicalTrials.gov |
What this trial studies
This observational trial evaluates the feasibility of using a mobile application to monitor patient-reported outcomes (PROs) in individuals with neuroendocrine tumors (NET). The app allows patients to document their symptoms and quality of life changes during and after treatment, facilitating better communication with healthcare providers. By capturing daily symptom data and utilizing validated questionnaires, the study aims to assess the impact of mobile technology on patient care and clinician responsiveness. The trial is non-invasive and encourages patient engagement in their treatment journey.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and over with a confirmed diagnosis of neuroendocrine tumors who are planning to undergo treatment.
Not a fit: Patients with concurrent malignancies, those without access to a smartphone, or individuals unable to complete questionnaires due to physical or psychological issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance symptom management and improve quality of life for patients with neuroendocrine tumors.
How similar studies have performed: While the use of mobile applications for symptom tracking is gaining traction, this specific approach in neuroendocrine tumors is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically confirmed diagnosis of a NET * Planned treatment for NET * Able to give informed consent * Able to understand the language of the questionnaires * A minimum expected survival of 6 months * All performance status is acceptable * 18 years of age or over Exclusion Criteria: * Concurrent malignancies for which they are undergoing treatment * No smartphone / device * Any physical, psychological or comprehension problems that prevents completion of questionnaires.
Where this trial is running
London
- King's College Hospital — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Raj Srirajaskanthan
- Email: r.srirajaskanthan@nhs.net
- Phone: 0203 299 3255
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.